Inno Medicine Participates in Compilation of "China Bioeconomy Development Report 2023" of China' s National Development and Reform Commission

Recently, the “China Bioeconomy Development Report 2023” was compiled by the Department for Innovation and High-Tech Development of China’s National Development and Reform Commission, the Innovation-Driven Development Center of the National Development and Reform Commission, and the Chinese Society Biotechnology, among other organizations. The Report was published by the Science Press. Dr. Ma Qian, Chairperson and CEO of Beijing Inno Medicine Co., Ltd., and Ms. Ji Fengyuan, Chief Operating Officer, participated as editors in the review of the report. An article titled “Nano-liposome Delivery Systems” authored by them was selected for inclusion in the “Future Bioeconomy Technologies” section of the report.

The “14th Five-Year Plan” and “China Bioeconomy Development Report 2023”

In the “Outline” of China’s 14th Five-Year Plan, a clear emphasis is placed on prioritizing the development of biopharma industry and expanding the bioeconomy into a major sector. In 2022, the National Development and Reform Commission issued the “14th Five-Year Plan for Bioeconomy Development”, highlighting the imperative to accelerate innovation and upgrading in the biopharma sector to facilitate high-quality development of the bioeconomy. Against that backdrop, the editorial committee of the “China Bioeconomy Development Report 2023” invited leading experts, scientists, and business elites in China’s biotechnology field to offer their professional insights and evaluations, strategic recommendations, and case studies for the high-quality development of China’s bioeconomy.

The nano-liposome delivery system is a technology that holds immense promise for the future of bioeconomy

The report takes a forward-looking perspective to introduce and elaborate on six future technologies for bioeconomy. Among them, the “Nano-liposome Delivery Systems” was selected to merit a dedicated chapter in the report. The remarkable potential of the technology was recognized by all the industry experts.

The report explains that nano-liposome, being a premium drug product that has been commercialized very successfully, is undergoing rapid evolution. With the ongoing iterations of the core technologies, significant breakthroughs are being achieved on the application of nano-liposomes in the fields of gene therapy and vaccines, garnering high recognition in the pharma industry. Serving as a platform, nano-liposomes have the potential to find applications in a wide array of products and indications, as drug delivery technologies continue to advance. Companies that possess these high-threshold technologies will enjoy a more solid competitive edge in the future market.

Structure of a nano-liposome

Over a span of seven years, Inno Medicine has been at the forefront of developing China’s first active targeted nano-liposome delivery platform. By encapsulating drugs in nano-liposomes, this platform enhances the drug’s bioavailability while significantly reducing its toxicity. Simultaneously, it achieves precise drug delivery to disease targets, thereby enhancing therapeutic efficiency. Leveraging its proprietary targeted nano-drug delivery platform, Inno Medicine is dedicated to addressing vast unmet clinical needs. With its clinical and commercial manufacturing capabilities, the Company expedites the discovery, development, and commercialization of novel drugs. At present, Inno Medicine has independently developed product pipelines targeting various therapeutic areas, including cardiovascular diseases and brain glioma. Looking ahead, Inno Medicine remains committed to a scientific and efficient approach to innovation. By harnessing the advantages of its platform, diversifying its pipeline, and expanding into new therapeutic areas, the Company is poised to contribute new wisdom and solutions to the growth of China’s bioeconomy.